Melanoma Vaccine Trial Fast-Tracked by NHS

[{"selector":"#anim-026e2696-f66c-4703-ab6c-0b327d7ae609","keyframes":{"opacity":[0,1]},"delay":500,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2e64b596-905b-4540-bd13-f893fa7667a0","keyframes":{"transform":["translate3d(-114.55696%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":500,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1bb24633-a509-4d46-9bfe-0bd5c5ccba82","keyframes":{"opacity":[0,1]},"delay":800,"duration":500,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f0783d0b-9391-4921-a102-32be38f6512a","keyframes":{"transform":["translate3d(-122.3301%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":800,"duration":500,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Melanoma Vaccine Trial Fast-Tracked by NHS Tejal Somvanshi

NHS England has expanded its Cancer Vaccine Launch Pad program to give advanced melanoma patients quick access to a promising new vaccine trial.

[{"selector":"#anim-188f86e1-dca5-4779-acd5-e2cf7fb55a52","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c49d8561-464a-4bc3-a2f6-4c423720e865","keyframes":{"transform":["translate3d(115.50632%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-cd10276e-d984-40d8-927d-18c72597df0b","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f29becf4-c2fc-4749-82f4-691a79a7634c","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7a7e52a0-7f62-497e-81c4-32271daabeab","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7adf82d9-9da4-4bb5-82f1-0afbe607d694","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source - Camosun College (CC BY-NC-ND 2.0) Representative Image

The iSCIB1+ vaccine, developed by UK company Scancell, helps the immune system spot and attack cancer cells - potentially stopping melanoma from coming back.

[{"selector":"#anim-36f65d44-3c3f-4543-8d1e-3975d6603cdb","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f7898172-a169-47fe-9350-d0d13de08719","keyframes":{"transform":["translate3d(0px, 163.7807%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0cbfc0d5-ab4e-481c-841c-ce0dcaaa984a","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-609adc40-c039-4264-a5ae-1a7da180d8f0","keyframes":{"transform":["translate3d(0px, -111.1955%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-cd7368a0-0b6b-4f44-b86f-5d7e6ef7d4ae","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a95a0d7d-dc3c-447a-93b7-e875089f61e7","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source - NIAID (CC BY 2.0) Representative Image

Melanoma cases have risen by a third over ten years, making this trial crucial for the fifth most common cancer in the UK.

[{"selector":"#anim-b2d89ae6-8098-49b4-8b01-04a59d84f222","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-70716b49-4a1d-46c2-8f53-0b1d8c4494ba","keyframes":{"transform":["translate3d(0px, 116.58885%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-fd6ae3a0-a134-4027-a211-f04309a6a8ca","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f1a6c9d2-8e0a-4ede-aa19-6c6b84c2784a","keyframes":{"transform":["translate3d(113.60759%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d567611d-3b4f-49c4-9e65-d7b747dbae7f","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-86ead69d-03e2-4429-92d6-58d5eaba2a8c","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source - NIH Image Gallery (CC BY-NC 2.0) Representative Image

Unlike standard treatments that only work for half of patients, this vaccine targets specific markers on tumor cells to boost the body's natural defenses.

[{"selector":"#anim-6ad9a34d-b17f-4308-904a-b1e21955f5a4","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-15b8054d-8431-4b58-acce-893f8752cd75","keyframes":{"transform":["translate3d(0px, 163.7807%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f078afcd-e6b9-4c1c-98ef-a6fa4a025e93","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c9d6bd12-aeae-4316-87c8-7440c1844195","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7e5d1880-867b-4530-9bf2-731a0263994d","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6dbcb621-1244-4b20-938f-74d8a41b4ffb","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source - NIH Image Gallery (PDM 1.0) Representative Image

My tumors have all shrunk since joining the trial," says 63-year-old Paul Thomas, who faced recurring skin cancer since 2017.

[{"selector":"#anim-816d8331-10e5-48ac-90e6-c2a6a93eefba","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ecb28955-9b42-4514-a417-eda6fce6b543","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9ae975e9-8395-4dc9-ae83-c2cf1ea4019e","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-3a279566-e427-46f4-bc0b-69727c3727e4","keyframes":{"transform":["translate3d(114.87342%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5cd45257-dc9b-4506-a1f3-f41b2a54d8e7","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9638dcc3-fc4f-4148-8c3d-bb6bc5d45c5a","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source - SHVETS production (Pexels) Representative Image

Seven hospital sites will initially offer the needle-free treatment, with patient referrals beginning next month as researchers aim to enroll dozens by October.

[{"selector":"#anim-979dd880-9639-42dd-a3e7-8b8f4037f487","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-dbe37acd-78ca-485d-bc0a-12eb72d3aa61","keyframes":{"transform":["translate3d(0px, 163.7807%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6ea7855d-e162-46ba-b9c3-46f5b35cd1cf","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4190953d-e314-4100-aff4-0c16e869faf3","keyframes":{"transform":["translate3d(0px, -114.48664%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8946c430-56a0-4220-a25e-75f958c85627","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-97598ef9-1484-45ee-a7fc-0ac717672af0","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source -Marta Branco (Pexels) Representative Image

The trial forms part of an ambitious NHS plan to provide personalized cancer treatments to 10,000 patients by 2030, with results expected in mid-to-late 2025.

[{"selector":"#anim-6443e68c-d083-431a-9368-e9313fa3c29d","keyframes":{"opacity":[0,1]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-3649a0fe-da1e-489a-8ebd-72637556f0d2","keyframes":{"transform":["translate3d(0px, 116.02864%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f8bd60ef-6a15-465b-a761-0b727c9c575e","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1368d9dc-4f3f-44da-9fab-d02e1769306f","keyframes":{"transform":["translate3d(115.18987%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a9654db1-81f8-4f2b-9709-fa233c0987cd","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-945e58ba-4b9d-467f-86f1-489f755cd0e1","keyframes":{"opacity":[0,1]},"delay":1400,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Photo Source -Jo McNamara (Pexels) Representative Image

[{"selector":"#anim-b4cf61e5-efad-429a-9f81-74c18791b3b2","keyframes":{"opacity":[0,1]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-85b921b6-63cf-44c5-936e-a7a16548cfb3","keyframes":{"opacity":[0,1]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4d90f73d-8fc4-4ee1-832f-a1787d3c6f80","keyframes":{"transform":["translate3d(-114.50152%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":200,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0e0018df-000c-4504-89ce-2731e3c93154","keyframes":{"opacity":[0,1]},"delay":700,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f615922a-6bba-47fc-b34b-8e519a33317b","keyframes":{"transform":["translate3d(115.2381%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":700,"duration":3000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Rivian's California Dune Edition: 850 HP, 2.9s 0-60 Learn more